Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-319 |
Synonyms | |
Therapy Description |
ABBV-319 is an antibody-drug conjugate (ADC) comprising an anti-CD19 antibody linked to a glucocorticoid receptor modulator agonist, which potentially inhibits tumor cell proliferation and decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): 6308). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-319 | ABBV319|ABBV 319 | CD19 Antibody 21 | ABBV-319 is an antibody-drug conjugate (ADC) comprising an anti-CD19 antibody linked to a glucocorticoid receptor modulator agonist, which potentially inhibits tumor cell proliferation and decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): 6308). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05512390 | Phase I | ABBV-319 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | ISR | CAN | AUS | 0 |